Abstract
Although there is substantial risk to maternal and neonatal health in the situation of pregnancy during treatment for rifampicin-resistant tuberculosis (RR-TB), there is little evidence to guide clinicians as to how to manage this complexity. Of the 49 680 patients initiated on RR-TB treatment from 2009 to 2014 in South Africa, 47% were women and 80% of them were in their reproductive years (15 - 44). There is an urgent need for increased evidence of the safety of RR-TB treatment during pregnancy, increased access to contraception during RR-TB treatment, and inclusion of reproductive health in research on the prevention and treatment of TB.
Publication types
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, Non-P.H.S.
MeSH terms
-
Adolescent
-
Adult
-
Antibiotics, Antitubercular / adverse effects
-
Antibiotics, Antitubercular / therapeutic use*
-
Contraception
-
Evidence-Based Medicine
-
Female
-
Humans
-
Male
-
Pregnancy
-
Pregnancy Complications, Infectious / drug therapy*
-
Pregnancy Complications, Infectious / epidemiology
-
Pregnancy Complications, Infectious / prevention & control
-
Rifampin / adverse effects
-
Rifampin / therapeutic use*
-
South Africa / epidemiology
-
Tuberculosis, Multidrug-Resistant / drug therapy*
-
Tuberculosis, Multidrug-Resistant / epidemiology
-
Tuberculosis, Multidrug-Resistant / prevention & control
-
Young Adult
Substances
-
Antibiotics, Antitubercular
-
Rifampin